Urogen Pharma (0XOD) Share Forecast & Price Target

Compare

0 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

0XOD Analyst Ratings

Strong Buy

5 Buy

0 Hold

0 Sell

Based on 5 analysts giving stock ratings to

Urogen

Pharma

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

0XOD Stock 12 Month Forecast

Average Price Target

$39.40

▲(71.23% Upside)

Based on 5 Wall Street analysts offering 12 month price targets for Urogen Pharma in the last 3 months. The average price target is $39.40 with a high forecast of $55.00 and a low forecast of $31.00. The average price target represents a 71.23% change from the last price of $23.01.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"3":"$3","56":"$56","16.25":"$16.25","29.5":"$29.5","42.75":"$42.8"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":55,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$55.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":39.4,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$39.40</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":31,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$31.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[3,16.25,29.5,42.75,56],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Feb<br/>2025","6":"May<br/>2025","9":"Aug<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.18,22.858461538461537,25.536923076923078,28.215384615384615,30.893846153846155,33.57230769230769,36.25076923076923,38.92923076923077,41.607692307692304,44.286153846153844,46.964615384615385,49.64307692307692,52.32153846153846,{"y":55,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.18,21.658461538461538,23.136923076923075,24.615384615384613,26.09384615384615,27.57230769230769,29.05076923076923,30.529230769230768,32.00769230769231,33.48615384615384,34.964615384615385,36.443076923076916,37.92153846153846,{"y":39.4,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,20.18,21.012307692307694,21.844615384615384,22.676923076923078,23.50923076923077,24.341538461538462,25.173846153846153,26.006153846153847,26.838461538461537,27.67076923076923,28.503076923076925,29.335384615384616,30.167692307692306,{"y":31,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":12.196,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 9,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":12.861,"date":1733011200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 9, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.81,"date":1735689600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 11, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.342,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":9.145,"date":1740787200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 4, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":10.96,"date":1743465600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 10,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":11.22,"date":1746057600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 15,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 16, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":4.628,"date":1748736000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 19, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":13.595,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 18, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.267,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 20,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 12, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":19.22,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 13,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 7, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":18.456,"date":1759276800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 5, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":20.18,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 7,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 3, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$55.00

Average Price Target$39.40

Lowest Price Target$31.00

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Leland Gershell

Oppenheimer

$31

Buy

34.72%

Upside

Reiterated

11/07/25

Oppenheimer Remains a Buy on Urogen Pharma (URGN)

Aydin Huseynov

Ladenburg Thalmann & Co.

$55

Buy

139.03%

Upside

Reiterated

11/07/25

Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Urogen Pharma (URGN)We reiterate our Buy rating and $55 price target.

Tara Bancroft

TD Cowen

$35

Buy

52.11%

Upside

Reiterated

11/06/25

Urogen Pharma's Promising Growth and Demand Surge Support Buy Rating

Ram Selvaraju

H.C. Wainwright

$40

Buy

73.84%

Upside

Reiterated

10/28/25

Analysts' Top Healthcare Picks: Urogen Pharma (URGN), AngioDynamics (ANGO)we reiterate our Buy rating and 12‐month price target of $40

Kelsey Goodwin

Piper Sandler

$36

Buy

56.45%

Upside

Reiterated

08/29/25

Piper Sandler Remains a Buy on Urogen Pharma (URGN)

Michael Schmidt

Guggenheim

$30→$32

Buy

39.07%

Upside

Reiterated

08/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

George Farmer

Scotiabank

$47

Buy

104.26%

Upside

Reiterated

08/06/25

Scotiabank Reaffirms Their Buy Rating on Urogen Pharma (URGN)

Paul Choi

Goldman Sachs

$3→$16

Hold

-30.47%

Downside

Reiterated

06/13/25

UroGen Pharma price target raised to $16 from $3 at Goldman SachsUroGen Pharma price target raised to $16 from $3 at Goldman Sachs

Jason Kolbert

D. Boral Capital

$25

Buy

8.65%

Upside

Reiterated

06/12/25

UroGen's Zusduri approval validates FDA's flexibility, says D. BoralUroGen's Zusduri approval validates FDA's flexibility, says D. Boral

John Ransom

Raymond James

$40→$36

Buy

56.45%

Upside

Reiterated

03/11/25

UroGen Pharma (URGN) PT Lowered to $36 at Raymond JamesRaymond James analyst Reni Benjamin lowered the price target on UroGen Pharma (NASDAQ: URGN) to $36.00 (from $40.00) while maintaining a Outperform rating.

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Leland Gershell

Oppenheimer

$31

Buy

34.72%

Upside

Reiterated

11/07/25

Oppenheimer Remains a Buy on Urogen Pharma (URGN)

Aydin Huseynov

Ladenburg Thalmann & Co.

$55

Buy

139.03%

Upside

Reiterated

11/07/25

Ladenburg Thalmann & Co. Sticks to Its Buy Rating for Urogen Pharma (URGN)We reiterate our Buy rating and $55 price target.

Tara Bancroft

TD Cowen

$35

Buy

52.11%

Upside

Reiterated

11/06/25

Urogen Pharma's Promising Growth and Demand Surge Support Buy Rating

Ram Selvaraju

H.C. Wainwright

$40

Buy

73.84%

Upside

Reiterated

10/28/25

Analysts' Top Healthcare Picks: Urogen Pharma (URGN), AngioDynamics (ANGO)we reiterate our Buy rating and 12‐month price target of $40

Kelsey Goodwin

Piper Sandler

$36

Buy

56.45%

Upside

Reiterated

08/29/25

Piper Sandler Remains a Buy on Urogen Pharma (URGN)

Michael Schmidt

Guggenheim

$30→$32

Buy

39.07%

Upside

Reiterated

08/07/25

Wall Street Analysts Are Bullish on Top Healthcare Picks

George Farmer

Scotiabank

$47

Buy

104.26%

Upside

Reiterated

08/06/25

Scotiabank Reaffirms Their Buy Rating on Urogen Pharma (URGN)

Paul Choi

Goldman Sachs

$3→$16

Hold

-30.47%

Downside

Reiterated

06/13/25

UroGen Pharma price target raised to $16 from $3 at Goldman SachsUroGen Pharma price target raised to $16 from $3 at Goldman Sachs

Jason Kolbert

D. Boral Capital

$25

Buy

8.65%

Upside

Reiterated

06/12/25

UroGen's Zusduri approval validates FDA's flexibility, says D. BoralUroGen's Zusduri approval validates FDA's flexibility, says D. Boral

John Ransom

Raymond James

$40→$36

Buy

56.45%

Upside

Reiterated

03/11/25

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Urogen Pharma

1 Month

xxx

Success Rate

13/24 ratings generated profit

Average Return

+17.35%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 1 Month would result in 54.17% of your transactions generating a profit, with an average return of +17.35% per trade.

3 Months

xxx

Success Rate

14/24 ratings generated profit

Average Return

+28.09%

reiterated a xxx

rating 5 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 58.33% of your transactions generating a profit, with an average return of +28.09% per trade.

1 Year

Tara BancroftTD Cowen

Success Rate

9/12 ratings generated profit

Average Return

+24.43%

reiterated a buy rating 6 days ago

Copying Tara Bancroft's trades and holding each position for 1 Year would result in 75.00% of your transactions generating a profit, with an average return of +24.43% per trade.

2 Years

xxx

Success Rate

12/12 ratings generated profit

Average Return

+41.47%

reiterated a xxx

rating 6 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +41.47% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

0XOD Analyst Recommendation Trends

Rating

Jul 25

Aug 25

Sep 25

Oct 25

Nov 25

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, 0XOD has received 7 Buy Ratings, 3 Hold Ratings, and 0 Sell Ratings. 0XOD average Analyst price target in the past 3 months is 39.40.

Each month's total comprises the sum of three months' worth of ratings.

0XOD Financial Forecast

0XOD Earnings Forecast

Next quarter’s earnings estimate for 0XOD is -$0.48 with a range of -$0.74 to -$0.18. The previous quarter’s EPS was -$0.69. 0XOD beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.09% of the time in the same period. In the last calendar year 0XOD has Performed in-line its overall industry.

0XOD Sales Forecast

Next quarter’s sales forecast for 0XOD is $41.45M with a range of $32.86M to $51.57M. The previous quarter’s sales results were $27.48M. 0XOD beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 47.55% of the time in the same period. In the last calendar year 0XOD has Performed in-line its overall industry.

0XOD Stock Forecast FAQ

What is GB:0XOD’s average 12-month price target, according to analysts?

Based on analyst ratings, Urogen Pharma’s 12-month average price target is 39.40.

What is GB:0XOD’s upside potential, based on the analysts’ average price target?

Urogen Pharma has 71.23% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is Urogen Pharma a Buy, Sell or Hold?

Urogen Pharma has a consensus rating of Strong Buy, which is based on 5 buy ratings, 0 hold ratings and 0 sell ratings.

What is Urogen Pharma’s share price target?

The average share price target for Urogen Pharma is 39.40. This is based on 5 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst share price target is $55.00 ,and the lowest forecast is $31.00. The average share price target represents 71.23% Increase from the current price of $23.01.

What do analysts say about Urogen Pharma?

Urogen Pharma’s analyst rating consensus is a Strong Buy. This is based on the ratings of 5 Wall Streets Analysts.

How can I buy shares of Urogen Pharma?

To buy shares of GB:0XOD, you can open a brokerage account. See exclusive account opening deals on our Best Online Brokers page.

Become an Expert with TipRanks Premium

What am I Missing?

Make informed decisions based on Top Analysts' activity

Know what industry insiders are buying

Get actionable alerts from top Wall Street Analysts

Find out before anyone else which stock is going to shoot up

Get powerful stock screeners & detailed portfolio analysis

Subscribe Now See Plans & Pricing

Urogen Pharma (0XOD) Share Forecast & Price Target

0XOD Analyst Ratings

0XOD Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Urogen Pharma

0XOD Analyst Recommendation Trends

0XOD Financial Forecast

0XOD Earnings Forecast

0XOD Sales Forecast

0XOD Stock Forecast FAQ

Become an Expert with TipRanks Premium

Detailed List of Analyst Forecasts